- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.06. | ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step change in prostate cancer | ||
| 02.06. | Why US-manufactured pharmaceutical packaging equipment matters | ||
| 01.06. | RallyBio tries again for reverse merger, this time with Avenzo | ||
| 01.06. | Servier buys into muscular dystrophy with potentially $2.7B deal | ||
| 01.06. | 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters? | ||
| 29.05. | At ASCO, Merck makes case for a 'cornerstone' cancer drug | ||
| 29.05. | Bristol Myers unveils data for one of its next-gen blood cancer drugs | ||
| 29.05. | Replimune takes third swing at cancer drug approval following 'productive' FDA talks | ||
| 29.05. | Allogene CEO to step down; Agios drug fails key test | ||
| 29.05. | Can a chaotic FDA still deliver on faster drug development? | ||
| 29.05. | Pfizer, Innovent strike $10B cancer drug deal | ||
| 28.05. | GSK, Ionis unveil data for hepatitis B drug touted as 'functional cure' | ||
| 28.05. | CVS obesity drug deal puts Lilly on equal footing with Novo | ||
| 27.05. | Verge, following trial failure, rebrands its AI drug discovery ambitions | ||
| 27.05. | FDA delays decision on AstraZeneca breast cancer pill | ||
| 27.05. | Cardio drugmaker Kardigan plans to go public | ||
| 27.05. | Kailera's three-pronged obesity shot shows promise in early trial | ||
| 27.05. | Apogee eczema drugs gets Blackstone backing, heads to Phase 3 | ||
| 26.05. | Early data for heart drug affirm Lilly's billion-dollar bet on Verve | ||
| 26.05. | Lilly dives into vaccine research with 3 biotech buyouts | ||
| 26.05. | Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine | ||
| 26.05. | SR One's Simeon George on how China is rewriting biotech's venture playbook | ||
| 26.05. | Process intensification: Separating fact from fiction | ||
| 26.05. | Measuring what matters: New priorities in COA selection | ||
| 22.05. | ASCO26: 5 data snapshots ahead of the year's biggest cancer drug meeting |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.